Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.
Current Team (4)Update
Funding Rounds (7) - $132.2MUpdate
Scottish Equity Partners is a venture capital firm investing in technology-based companies in the...
200 Connell Drive #1500
Berkeley Heights, NJ 07922
Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering | Philadelphia Citybizlistphiladelphia.citybizlist.com